Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-28T17:52:12.308Z Has data issue: false hasContentIssue false
  • English
  • Français

Quality of inpatient antimicrobial use in hematology and oncology patients

Published online by Cambridge University Press:  01 February 2021

Abby P. Douglas Open the ORCID record for Abby P. Douglas [Opens in a new window] ,
Lisa Hall ,
Rodney S. James ,
Leon J. Worth ,
Monica A. Slavin  and
Karin A. Thursky
Abby P. Douglas*
Affiliation:
Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia University of Melbourne, Melbourne, Victoria, Australia The National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Lisa Hall
Affiliation:
The National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia University of Queensland, Brisbane, Queensland, Australia
Rodney S. James
Affiliation:
National Centre for Antimicrobial Stewardship, The Peter Doherty Institute of Infection and Immunity, Melbourne, Victoria, Australia
Leon J. Worth
Affiliation:
Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia University of Melbourne, Melbourne, Victoria, Australia The National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia National Centre for Antimicrobial Stewardship, The Peter Doherty Institute of Infection and Immunity, Melbourne, Victoria, Australia
Monica A. Slavin
Affiliation:
Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia University of Melbourne, Melbourne, Victoria, Australia The National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia Victorian Infectious Diseases Service, The Peter Doherty Institute for Immunity and Infection, Royal Melbourne Hospital, Melbourne, Victoria, Australia
Karin A. Thursky
Affiliation:
Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia University of Melbourne, Melbourne, Victoria, Australia The National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia National Centre for Antimicrobial Stewardship, The Peter Doherty Institute of Infection and Immunity, Melbourne, Victoria, Australia Victorian Infectious Diseases Service, The Peter Doherty Institute for Immunity and Infection, Royal Melbourne Hospital, Melbourne, Victoria, Australia
*
Author for correspondence: Dr Abby Douglas, E-mail: abby.douglas@petermac.org
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives:

To compare antimicrobial prescribing practices in Australian hematology and oncology patients to noncancer acute inpatients and to identify targets for stewardship interventions.

Design:

Retrospective comparative analysis of a national prospectively collected database.

Methods:

Using data from the 2014–2018 annual Australian point-prevalence surveys of antimicrobial prescribing in hospitalized patients (ie, Hospital National Antimicrobial Prescribing Survey called Hospital NAPS), the most frequently used antimicrobials, their appropriateness, and guideline concordance were compared among hematology/bone marrow transplant (hemBMT), oncology, and noncancer inpatients in the setting of treatment of neutropenic fever and antibacterial and antifungal prophylaxis.

Results:

In 454 facilities, 94,226 antibiotic prescriptions for 62,607 adult inpatients (2,230 hemBMT, 1,824 oncology, and 58,553 noncancer) were analyzed. Appropriateness was high for neutropenic fever management across groups (83.4%–90.4%); however, hemBMT patients had high rates of carbapenem use (111 of 746 prescriptions, 14.9%), and 20.2% of these prescriptions were deemed inappropriate. Logistic regression demonstrated that hemBMT patients were more likely to receive appropriate antifungal prophylaxis compared to oncology and noncancer patients (adjusted OR, 5.3; P < .001 for hemBMT compared to noncancer patients). Oncology had a low rate of antifungal prophylaxis guideline compliance (67.2%), and incorrect dosage and frequency were key factors. Compared to oncology patients, hemBMT patients were more likely to receive appropriate nonsurgical antibacterial prophylaxis (aOR, 8.4; 95% CI, 5.3–13.3; P < .001). HemBMT patients were also more likely to receive appropriate nonsurgical antibacterial prophylaxis compared to noncancer patients (OR, 3.1; 95% CI, 1.9–5.0; P < .001). However, in the Australian context, the hemBMT group had higher than expected use of fluoroquinolone prophylaxis (66 of 831 prescriptions, 8%).

Conclusions:

This study demonstrates why separate analysis of hemBMT and oncology populations is necessary to identify specific opportunities for quality improvement in each patient group.

Type
Original Article
Information
Infection Control & Hospital Epidemiology , Volume 42 , Issue 10 , October 2021 , pp. 1235 - 1244
Check for updates
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

PREVIOUS PRESENTATION. An abstract of these data was presented at IDWeek 2019 on October 4, 2019, in Washington, DC.

References

Abbo, LM, Ariza-Heredia, EJ. Antimicrobial stewardship in immunocompromised hosts. Infect Dis Clin North Am 2014;28:263–279.CrossRefGoogle ScholarPubMed
Gudiol, C, Carratala, J. Antibiotic resistance in cancer patients. Expert Rev Anti Infect Ther 2014;12:1003–1016.CrossRefGoogle ScholarPubMed
Robilotti, E, Holubar, M, Seo, SK, et al. Feasibility and applicability of antimicrobial stewardship in immunocompromised patients. Curr Opin Infect Dis 2017;30:346–353.CrossRefGoogle ScholarPubMed
Seo, SK, Lo, K, Abbo, LM. Current state of antimicrobial stewardship at solid organ and hematopoietic cell transplant centers in the United States. Infect Control Hosp Epidemiol 2016;37:1195–1200.CrossRefGoogle ScholarPubMed
Trubiano, JA, Worth, LJ, Thursky, KA, et al. The prevention and management of infections due to multidrug resistant organisms in haematology patients. Br J Clin Pharmacol 2015;79:195–207.CrossRefGoogle ScholarPubMed
Fleming-Dutra, KE, Hersh, AL, Shapiro, DJ, et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010–2011. JAMA 2016;315:1864–1873.CrossRefGoogle ScholarPubMed
Krantz, EM, Zier, J, Stohs, E, et al. Antibiotic prescribing and respiratory viral testing for acute upper respiratory infections among adult patients at an ambulatory cancer center. Clin Infect Dis 2020;70:1421–1428.CrossRefGoogle ScholarPubMed
Responding to the threat of antimicrobial resistance: Australia’s First National Antimicrobial Resistance Strategy 2015–2019. Australian Government Antimicrobial Resistance website. https://www.amr.gov.au/resources/national-amr-strategy. Published 2015. Accessed August 4, 2020.Google Scholar
Third Australian report on antimicrobial use and resistance in human health - AURA 2019 - May 2019. Australian National Safety and Quality Health Service website. https://www.safetyandquality.gov.au/our-work/antimicrobial-resistance/antimicrobial-use-and-resistance-australia-surveillance-system-aura/aura-2019. Published 2019. Accessed August 4, 2020.Google Scholar
National Antimicrobial Prescribing Survey. NAPS website. https://naps.org.au. Accessed January 5, 2021.Google Scholar
The National Safety and Quality Health Service (NSQHS) standards. Australian National Safety and Quality Health Service website. https://www.safetyandquality.gov.au/standards/nsqhs-standards. Accessed August 4, 2020.Google Scholar
James, R, Upjohn, L, Cotta, M, et al. Measuring antimicrobial prescribing quality in Australian hospitals: development and evaluation of a national antimicrobial prescribing survey tool. J Antimicrob Chemother 2015;70:1912–1918.Google ScholarPubMed
Therapeutic guidelines: Antibiotic. Australian Therapeutic Guidelines website. www.tg.org.au. Accessed August 4, 2020.Google Scholar
National Centre for Antimicrobial Stewardship and Australian Commission on Safety and Quality in Health Care. Antimicrobial Prescribing Practice in Australian Hospitals: Results of the 2016 Hospital National Antimicrobial Prescribing Survey. Sydney: ACSQHC; 2018.Google Scholar
Ierano, C, Thursky, K, Marshall, C, et al. Appropriateness of surgical antimicrobial prophylaxis practices in Australia. JAMA Netw Open 2019;2:e1915003.CrossRefGoogle ScholarPubMed
McMullan, BJ, Hall, L, James, R, et al. Antibiotic appropriateness and guideline adherence in hospitalized children: results of a nationwide study. J Antimicrob Chemother 2020;75:738–7346.Google ScholarPubMed
Cornely, OA, Leguay, T, Maertens, J, et al. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. J Antimicrob Chemother 2017;72:2359–2367.CrossRefGoogle ScholarPubMed
Penack, O, Schwartz, S, Martus, P, et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 2006;17:1306–1312.CrossRefGoogle ScholarPubMed
Agarwal, SK, DiNardo, CD, Potluri, J, et al. Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther 2017;39:359–367.CrossRefGoogle ScholarPubMed
de Zwart, L, Snoeys, J, De Jong, J, et al. Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling. Clin Pharmacol Ther 2016;100:548–557.CrossRefGoogle ScholarPubMed
Moriyama, B, Henning, SA, Leung, J, et al. Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses 2012;55:290–297.CrossRefGoogle ScholarPubMed
Fleming, S, Yannakou, CK, Haeusler, GM, et al. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014. Intern Med J 2014;44:1283–1297.CrossRefGoogle ScholarPubMed
Khanina, A, Douglas, AP, Thursky, KA. Implementation of effective antifungal stewardship in cancerpatients—a review of current evidence. Curr Fungal Infect Rept 2020;14(3):1–12.Google Scholar
Khanina, A, Urbancic, K, Haeusler, GM, et al. Establishing essential metrics for antifungal stewardship in hospitals: the results of an international Delphi survey. J Antimicrob Chemother 2021;76:253–262.CrossRefGoogle ScholarPubMed
Gram-Negative Sepsis Outcome Program 2018 report. Australian Group on Antimicrobial Resistance website. https://agargroup.org.au/agar-surveys-Gram-Negative-Bacteria. Published 2018. Accessed June 3, 2020.Google Scholar
FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. US Food and Drug Administration website. https://www.fda.gov/media/119532/download. Accessed June 3, 2020.Google Scholar
Macesic, N, Morrissey, CO, Cheng, AC, et al. Changing microbial epidemiology in hematopoietic stem cell transplant recipients: increasing resistance over a 9-year period. Transpl Infect Dis 2014;16:887–896.CrossRefGoogle Scholar
Taur, Y, Pamer, EG. Microbiome mediation of infections in the cancer setting. Genome Med 2016;8:40.CrossRefGoogle ScholarPubMed
Slavin, MA, Worth, LJ, Seymour, JF, et al. Better sepsis management rather than fluoroquinolone prophylaxis for patients with cancer-related immunosuppression. J Clin Oncol 2019;37:1139–1140.CrossRefGoogle ScholarPubMed
Pillinger, KE, Bouchard, J, Withers, ST, et al. Inpatient antibiotic stewardship interventions in the adult oncology and hematopoietic stem cell transplant population: a review of the literature. Ann Pharmacother 2020;54:594–610.CrossRefGoogle ScholarPubMed
Drekonja, DM, Filice, GA, Greer, N, et al. Antimicrobial stewardship in outpatient settings: a systematic review. Infect Control Hosp Epidemiol 2015;36:142–152.CrossRefGoogle ScholarPubMed
Zetts, RM, Stoesz, A, Smith, BA, et al. Outpatient antibiotic use and the need for increased antibiotic stewardship efforts. Pediatrics 2018;141(6):e20174124.CrossRefGoogle ScholarPubMed
Rosa, RG, Goldani, LZ, dos Santos, RP. Association between adherence to an antimicrobial stewardship program and mortality among hospitalised cancer patients with febrile neutropaenia: a prospective cohort study. BMC Infect Dis 2014;14:286.CrossRefGoogle Scholar
Yeo, CL, Chan, DS, Earnest, A, et al. Prospective audit and feedback on antibiotic prescription in an adult hematology-oncology unit in Singapore. Eur J Clin Microbiol Infect Dis 2012;31:583–590.CrossRefGoogle Scholar
So, M, Mamdani, MM, Morris, AM, et al. Effect of an antimicrobial stewardship programme on antimicrobial utilisation and costs in patients with leukaemia: a retrospective controlled study. Clin Microbiol Infect 2018;24:882–888.CrossRefGoogle ScholarPubMed
Tam, CS, O’Reilly, M, Andresen, D, et al. Use of empiric antimicrobial therapy in neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee. Intern Med J 2011;41:90–101.CrossRefGoogle Scholar
Thursky, K, Lingaratnam, S, Jayarajan, J, et al. Implementation of a whole of hospital sepsis clinical pathway in a cancer hospital: impact on sepsis management, outcomes and costs. BMJ Open Qual 2018;7:e000355.CrossRefGoogle Scholar
Versporten, A, Zarb, P, Caniaux, I, et al. Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point-prevalence survey. Lancet Glob Health 2018;6:e619–e629.CrossRefGoogle ScholarPubMed
Australian hospital peer groups. Australian Institute of Health and Welfare website. https://www.aihw.gov.au/getmedia/79e7d756-7cfe-49bf-b8c0-0bbb0daa2430/14825.pdf.aspx?inline=true. Accessed June 3, 2020.Google Scholar
Australian Statistical Geography Standard (ASGS): volume 5—remoteness structure, July 2016. Australian Bureau of Statistics website. https://www.abs.gov.au/ausstats/abs@.nsf/mf/1270.0.55.005. Accessed August 4, 2020.Google Scholar
Blyth, CC, Gilroy, NM, Guy, SD, et al. Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014. Intern Med J 2014;44:1333–1349.CrossRefGoogle ScholarPubMed
Supplementary material: File

Douglas et al. supplementary material

Figure S1

Download Douglas et al. supplementary material(File)
File 375.1 KB
Supplementary material: File

Douglas et al. supplementary material

Tables S1 and S2

Download Douglas et al. supplementary material(File)
File 77.7 KB